COTA and the Food and Drug Administration (FDA) have partnered to utilize real-world evidence to generate new insight into the treatment of cancer, BioSpace reports.
The two-year partnership looks to develop a new study protocol, according to the report, and will first focus on breast cancer.
“As the oncology and precision medicine landscape continues to rapidly evolve, we are excited to be on the front lines, aiding in developing a strong understanding of the functions of RWE and improving the lives of cancer patients everywhere,” COTA CEO Mike Doyle said in a statement. “We’re honored to be partnering with the FDA to do our part in improving care for patients and helping to shape regulatory decision making.”
To read the full report on BioSpace, click here.